Obstructive sleep apnea (OSA) is highly prevalent, affecting 34% of men and 17% of women. 1 Individuals with OSA experience recurrent cardiometabolic stress when repetitively attempting to breathe against an occluded airway during sleep, leading to nightly episodes of hypoxia, sleep disruption, and surges of the sympathetic nervous system. These physiological perturbations often cause blood pressure and heart rate elevations, endothelial dysfunction, and insulin resistancemechanisms implicated in the pathogenesis of cardiovascular disease (CVD), diabetes, and neurologic disease. 2 When untreated, OSA is associated with an increased risk for incident hypertension, CVD, stroke, and mortality, 3 as well as increased sleepiness, motor vehicle crashes, and mood disorders and reduced quality of life. 4,5 Given its association with CVD, OSA has been proposed as a novel intervention target for reducing morbidity and mortality rates. The quest, however, to improve health by treating OSA requires rigorous research that evaluates the role of OSA interventions in large groups of patients followed up for long periods. Advancing this research agenda requires validated tools for screening appropriate populations and the availability of interventions that effectively treat OSA.In this issue of JAMA, the US Preventive Services Task Force (USPSTF) presents recommendations for screening asymptomatic primary care patients for OSA. 6 Based on a commissioned systematic review, 7 the USPSTF concluded that "the current evidence is insufficient to assess the balance of benefits and harms of screening for OSA in asymptomatic adults. (I statement)" 6 The determination of insufficient evidence was due to the absence of randomized trials assessing the effect of screening and of treatment on clinical outcomes; suboptimal performance characteristics of existing screening instruments; and concern over residual confounding in observational studies. 6,7 The high prevalence of undiagnosed OSA and its attendant morbidity and mortality provide a strong impetus to improve recognition of this disorder. Community-based studies demonstrate that OSA is highly prevalent and underdiagnosed across population groups, especially minorities. Among 14 440 participants in the Hispanic Community Health Study, prevalence of OSA was found to be 25.8% when participants underwent sleep testing. 8 In contrast, only 1.3% of cohort members reported an OSA diagnosis. Similarly, in a community sample of more than 2200